PAM
CORT icon

Paradigm Asset Management’s Corcept Therapeutics CORT Stock Holding History

Paradigm Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,800
Closed -$68.4K – 431
2017
Q2 		$68.4K Sell
5,800
-6,000
-51% -$65.2K 0.01% 475
2017
Q1 		$129K Buy
+11,800
New +$104K 0.02% 463
2015
Q4 		– Sell
-59,800
Closed -$225K – 803
2015
Q3 		$225K Buy
+59,800
New +$303K 0.03% 450

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paradigm Asset Management's CORT Position: Q3 2017 in Review

Paradigm Asset Management sold out of Corcept Therapeutics (CORT) in Q3 2017, closing a stake of 5,800 shares — an estimated $68.4K sold.

Paradigm Asset Management first reported a position in CORT in Q3 2015 and held it in 3 quarters. The position peaked at $225K in Q3 2015. 189 funds tracked by Wall St. Rank hold CORT as of Q3 2017.

  • Paradigm Asset Management reported no remaining Corcept Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Paradigm Asset Management sold 5,800 Corcept Therapeutics shares in Q3 2017, an estimated $68.4K.
  • Paradigm Asset Management first reported a position in Corcept Therapeutics in Q3 2015 and held it in 3 quarters.
  • Paradigm Asset Management's Corcept Therapeutics position peaked at $225K in Q3 2015.
  • 189 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.